Patent 11926645 was granted and assigned to Gilead Sciences on March, 2024 by the United States Patent and Trademark Office.
Compounds and methods of using said compounds, singly or in combination with additional agents, and salts, crystalline forms, pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.